56D3154E-E779-4C27-8305-FEE7310B6762
—
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- —
- overall_survival_months
- 23.160315374507228
- age_years
- 29
- sex
- Male
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- OXIDATIVE_PHOSPHORYLATION+0.630
- REACTIVE_OXYGEN_SPECIES_PATHWAY+0.505
- MYC_TARGETS_V1+0.501
- PROTEIN_SECRETION+0.466
- MTORC1_SIGNALING+0.394
- ADIPOGENESIS+0.360
- DNA_REPAIR+0.340
- FATTY_ACID_METABOLISM+0.325
- ANDROGEN_RESPONSE+0.324
- UNFOLDED_PROTEIN_RESPONSE+0.312
Top 10 suppressed
- IL6_JAK_STAT3_SIGNALING-0.428
- ANGIOGENESIS-0.391
- INTERFERON_GAMMA_RESPONSE-0.379
- EPITHELIAL_MESENCHYMAL_TRANSITION-0.378
- INTERFERON_ALPHA_RESPONSE-0.332
- ALLOGRAFT_REJECTION-0.318
- INFLAMMATORY_RESPONSE-0.309
- TNFA_SIGNALING_VIA_NFKB-0.270
- KRAS_SIGNALING_DN-0.237
- COAGULATION-0.233
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
9 twins match this tumor's tissue · 1 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | BB79CABB-0912-4E02-ACD9-82EF3AB8B598 | — | — | 0.878 |
| 2 | 5085CE66-190D-478B-9AB6-55AE71C41CCF | — | — | 0.842 |
| 3 | 3DC38276-A6D2-49C6-8F54-3F50F6BFAD0C | — | — | 0.834 |
| 4 | 28E176DE-49DB-4F39-B022-C89235590CAC | — | — | 0.831 |
| 5 | 02F669D8-FB9F-45AF-A999-5886E5C2DAF0 | — | — | 0.830 |
| 6 | SRR6013593 | — | cohortA1 | 0.827 |
| 7 | 0A4681EC-A57A-45CD-BB97-3E90A8CDECDD | — | — | 0.825 |
| 8 | SJEPD030784_D1.RNA-Seq | EPN | Myxopapillary EPN | 0.824 |
| 9 | SRR12696800 | — | — | 0.820 |
| 10 | TCGA-BH-A0H9-01A-11R-A056-07 | — | B | 0.818 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 28 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| OXIDATIVE_PHOSPHORYLATION | 0.630 | Remibrutinib | — uncovered |
| REACTIVE_OXYGEN_SPECIES_PATHWAY | 0.505 | Inavolisib | — uncovered |
| MYC_TARGETS_V1 | 0.501 | Inavolisib | — uncovered |
| PROTEIN_SECRETION | 0.466 | Remibrutinib | — uncovered |
| MTORC1_SIGNALING | 0.394 | Inavolisib | — uncovered |
| ADIPOGENESIS | 0.360 | Inavolisib | — uncovered |
| DNA_REPAIR | 0.340 | Idelalisib | — uncovered |
| FATTY_ACID_METABOLISM | 0.325 | Inavolisib | — uncovered |
| ANDROGEN_RESPONSE | 0.324 | Inavolisib | — uncovered |
| UNFOLDED_PROTEIN_RESPONSE | 0.312 | Idelalisib | — uncovered |
| UV_RESPONSE_UP | 0.308 | Idelalisib | — uncovered |
| UV_RESPONSE_DN | 0.246 | Inavolisib | — uncovered |
| HEME_METABOLISM | 0.232 | Temsirolimus | — uncovered |
| PANCREAS_BETA_CELLS | 0.225 | Cobimetinib | — uncovered |
| PEROXISOME | 0.219 | Idelalisib | — uncovered |
| PI3K_AKT_MTOR_SIGNALING | 0.205 | Inavolisib | — uncovered |
| TGF_BETA_SIGNALING | 0.176 | Inavolisib | — uncovered |
| MYC_TARGETS_V2 | 0.150 | Idelalisib | — uncovered |
| GLYCOLYSIS | 0.133 | Inavolisib | — uncovered |
| HEDGEHOG_SIGNALING | 0.095 | Inavolisib | — uncovered |